导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -14.23% | 4068/4773 |
| 近一周 | -1.89% | 842/5462 |
| 近一月 | -0.61% | 803/5421 |
| 近一季 | -7.98% | 2619/5209 |
| 近半年 | -16.87% | 4129/4920 |
| 近一年 | -1.81% | 2927/4366 |
| 近两年 | 42.38% | 1771/2954 |
| 近三年 | 12.52% | 1683/2253 |
| 成立以来 | 93.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.64% 3661/4961 |
-0.83% 3314/5312 |
- - |
- - |
| 2025 | 29.70% 1383/4813 |
-1.62% 2712/3635 |
11.30% 192/4076 |
6.87% 3498/4524 |
10.84% 177/4813 |
| 2024 | 7.92% 1605/3463 |
-5.85% 1958/2808 |
-2.43% 1188/3014 |
12.30% 2378/3129 |
4.63% 685/3463 |
| 2023 | -10.89% 1345/2656 |
1.17% 1625/2280 |
2.59% 129/2385 |
-10.35% 1988/2515 |
-4.23% 924/2655 |
| 2022 | -25.07% 1287/2207 |
-21.42% 1624/1919 |
3.51% 1140/2016 |
-6.98% 110/2113 |
-0.96% 1661/2208 |
| 2021 | 14.89% 319/1822 |
-17.66% 1202/1255 |
10.29% 480/1330 |
7.90% 171/1466 |
17.25% 44/1822 |
| 2020 | 70.72% 70/1250 |
-0.47% 187/1028 |
11.24% 739/1067 |
30.54% 10/1164 |
18.12% 102/1184 |
| 2019 | 21.75% 646/1092 |
29.42% 276/754 |
-8.80% 611/804 |
4.26% 207/850 |
-1.06% 895/918 |
| 2018 | -26.46% 386/834 |
- - |
- - |
- - |
-12.60% 461/691 |
| 2017 | -16.57% 570/714 |
- - |
- - |
- - |
- - |
| 2016 | -22.38% 459/605 |
- - |
- - |
- - |
- - |
| 2015 | 41.58% 40/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 申万菱信中证军工指数(LOF)A VS. 长安沪深300非周期A(740101) |